Arcturus Therapeutics Holdings Inc. (ARCT)
D
Pipeline Grade
Financial Position (from SEC Filings)
$213.4M
Cash & Equivalents
$19.4M
Quarterly Burn Rate
33 mo
Est. Cash Runway
$198M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-06-01 | Phase2 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06488313 | A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD | PHASE2 | Recruiting | 9 |
| NCT06747858 | Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis | PHASE2 | Recruiting | 33 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-07-02 | 8-K | Arcturus Therapeutics Holdings Inc. (ARCT) (CIK 0001768224) | EDGAR |